Feitsma EA, Janssen YF, Boersma HH, van Sleen Y, et al. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452. Vaccine 2023 Feb 23:S0264-410X(23)00200-1. doi: 10.1016/j.vaccine.2023.
PMID: 36842886